ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors

/PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been...

Related Keywords

Houston ,Texas ,United States ,Jennifer Guinan ,Prnewswire Immunogenesis ,James Barlow ,Jeremy Barton ,University Of Texas Md Anderson Cancer Center ,Cancer Focus Fund ,Research Institute Of Texas ,Cancer Center ,Immunogenesis President ,Immunogenesis Acting Chief Medical Officer ,Cancer Prevention ,Research Institute ,Strategic Marketing ,Immunogenesis ,